drugset

drugset / Trial / NCT00805909

NI-0401 in Patients With Acute Renal Allograft Rejection

NCT00805909 ↗

Phase 1/2 Completed 12 enrolled Light Chain Bioscience - Novimmune SA

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the safety and tolerability of NI-0401 and whether NI-0401 can reverse BpACR.

Timeline

Start: 2007-08
Primary completion: 2009-01
Completion: 2009-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Foralumab	Monoclonal antibody	—	—

Indications